A new oral vaccine for cholera, Euvichol-S, has received prequalification from the World Health Organization (WHO).

Key highlights:

  • This vaccine is manufactured by EuBiologicals Co., Ltd of Republic of Korea
  • The WHO’s prequalification list already includes Euvichol and Euvichol-Plus, also produced by EuBiologicals Co., Ltd.
  • Euvichol-S utilises a simplified formula with fewer ingredients, resulting in reduced production costs and faster manufacturing processes.


  • WHO’s approval allows donor agencies like Gavi and UNICEF to procure Euvichol-S for distribution in poorer countries, offering hope in combating cholera outbreaks.
  • It is estimated that approximately 50 million doses for the global stockpile will be available this year, up from 38 million doses in the previous year.


  • Despite progress, the demand for cholera vaccines remains high, with 14 affected countries requesting 79 million doses since January.
  • WHO reported a depletion of the global vaccine stockpile in early March, with only 2.3 million doses being available.

About Cholera:


  • Cholera is an acute diarrheal disease caused by the bacterium Vibrio cholerae 


  • It is primarily transmitted through contaminated food and water. 
  • It is most prevalent in regions with inadequate sanitation and limited access to clean water.


  • Most infected persons experience no symptoms (asymptomatic).
  • In severe cases, it can lead to profuse watery diarrhoea, vomiting, muscle cramps, rapid dehydration, and weakness.


  • Cholera treatment involves rehydration with oral or intravenous fluids and antibiotic therapy for severe cases.
  • Without treatment, cholera can be fatal, with mortality rates ranging from a quarter to half of those infected.


  • Clean Water and Sanitation: Access to clean water and proper sanitation is crucial for preventing cholera transmission.
  • Hygiene Practices: Promoting regular handwashing with soap and water is essential for reducing the risk of cholera infection.
  • Vaccination: Vaccination can provide added protection during outbreaks or in high-risk areas.

Global Impact and Recent Trends

  • Since January, the World Health Organization (WHO) has reported over 824,000 cholera infections and 5,900 deaths worldwide.
  • The highest concentrations of cases have been observed in the Middle East and Africa.
  • Warming temperatures, conducive to the survival of cholera bacteria, have exacerbated outbreaks. According to the WHO, it has led to the highest death rates in a decade.


With Euvichol-S’s increased availability, alongside a continued emphasis on sanitation and hygiene, there is hope for mitigating the impact of cholera in vulnerable communities and reducing its burden on public health.

Also Read:

26th World Energy Congress